BONTAGRRO
Live / Applied — Non-final action mailed (as of 08 Oct 2026)
What this means for you
Not registered yet, but its 03 Jun 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99862907
- Mark type
- Design + words
- Filed
- 03 Jun 2026
- Attorney of record
- Eric R. Moran
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals; pharmaceutical preparations; pharmaceutical products; biologics; biosimilars; filgrastim biosimilars; pharmaceutical preparations for the treatment of neutropenia; pharmaceutical preparations for the treatment of low white blood cells; pharmaceutical preparations for use in stimulating white blood cell production; biosimilars for use in stimulating white blood cell production; pharmaceutical preparations, namely, recombinant-human granulocyte-CSF for use in stimulating white blood cell production; recombinant-human granulocyte-CSF biosimilars for use in stimulating white blood cell production; pharmaceutical preparations, namely, injectable filgrastim biosimilars; pharmaceutical preparations, namely, injectable biosimilars for the treatment of neutropenia; pharmaceutical preparations, namely, injectable biosimilars for the treatment of low white blood cells; pharmaceutical preparations, namely, injectable biosimilars for use in stimulating white blood cell production; pharmaceutical preparations, namely, injectable recombinant-human granulocyte-CSF for use in stimulating white blood cell production; pharmaceutical preparations, namely, injectable recombinant-human granulocyte-CSF biosimilars for use in stimulating white blood cell production; injectors sold filled with filgrastim biosimilars; injectors sold filled with pharmaceutical preparations for the treatment of neutropenia; injectors sold filled with pharmaceutical preparations for the treatment of low white blood cells; injectors sold filled with pharmaceutical preparations for use in stimulating white blood cell production; injectors sold filled withbiosimilars for use in stimulating white blood cell production; injectors sold filled with recombinant-human granulocyte-CSF for use in stimulating white blood cell production; injectors sold filled with recombinant-human granulocyte-CSF biosimilars for use in stimulating white blood cell production
Owner
- Hong Kong King-Friend, Industrial Company, Ltd., Hong Kong, HK
Prosecution history
- 08 Oct 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 08 Oct 2026 — NON-FINAL ACTION E-MAILED
- 08 Oct 2026 — NON-FINAL ACTION WRITTEN
- 07 Oct 2026 — ASSIGNED TO EXAMINER
- 06 Oct 2026 — NOTICE OF DESIGN SEARCH CODE E-MAILED
- 06 Oct 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 03 Jun 2026 — APPLICATION FILING RECEIPT MAILED
- 03 Jun 2026 — NEW APPLICATION ENTERED